Hep Talk

Entry inhibitors usher in a new phase of hep C research by Larry Buhl Future therapy for hepatitis C infection may include a variety of drugs...

LifeGuide Hep Talk Who Benefits? Patient advocates decry restitutions on medications by Larry Buhl There is agreement in the medical community that a revolution is underway for the treatment...

Approved by the fda, telaprevir and boceprevir usher in a new era of treatment by Larry Buhl The first breakthrough treatments for liver disease to...

Amy Killelea of the National Alliance of State and Territorial AIDS Directors (NASTAD) sees healthcare coverage gaps everywhere, and as director of NASTAD’s new...

By the Numbers While HCV prevalence is down, the rate of morbidity may be going up by Larry Buhl New data on the prevalence of hepatitis C...

Awareness Is Key What You Need to Know About the Side Effect Profiles of New HCV Antiretrovirals by Larry Buhl By all accounts, adding the new direct-acting...

Last fall the New York State Department of Corrections and Community Supervision (DOCCS) ended its policy of excluding prisoners from any hepatitis C treatment...

Changing the Conversation A new storytelling campaign puts a human face on hep B by Larry Buhl Healthcare professionals agree that stigma around hepatitis is the biggest...

Denial Many states restrict DAA coverage to the sickest of hep C patients by Larry Buhl When direct-acting antiretrovirals (DAAs) for hepatitis C were new, some private...

Hep Talk by Larry Buhl Three Steps New hep C data sharing may lead to more testing Last year the U.S. Centers for Disease Control and Prevention...